Vaxil Bio (TSXV:VXL) OCF Margin %: 0.00% (As of Mar. 2026)


TSXV:VXL Vaxil Bio Ltd TSXV:VXL
38 GF Score
Price C$0.18
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio OCF Margin %?

Vaxil Bio TSXV:VXL 38 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TSXV:VXL with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Vaxil Bio ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Vaxil Bio's Cash Flow from Operations for the three months ended in Mar. 2026 was C$-0.14 Mil. Vaxil Bio's Revenue for the three months ended in Mar. 2026 was C$0.00 Mil. Therefore, Vaxil Bio's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Vaxil Bio's current OCF Yield % is -35.56%.

The historical rank and industry rank for Vaxil Bio's OCF Margin % or its related term are showing as below:


TSXV:VXL's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Vaxil Bio OCF Margin % Related Terms

Vaxil Bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio OCF Margin % Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:VXL
38GF Score
Vaxil Bio Ltd TSXV:VXL
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Vaxil Bio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.158/0
= %

Vaxil Bio's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.144/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Vaxil Bio (TSXV:VXL) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vaxil Bio and its competitors. According to the industry distribution chart, Vaxil Bio ranks #999999 out of 960 companies in the Biotechnology industry.
Is Vaxil Bio's OCF Margin % too high?
Vaxil Bio's current OCF Margin % is 0.00%. Based on the distribution chart, Vaxil Bio ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #999999 out of 960 companies for OCF Margin %. This places Vaxil Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (TSXV:VXL) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Vaxil Bio (TSXV:VXL), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXLLF:USA
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score

Get the complete analysis for TSXV:VXL

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.18
Price